Muhammad Riyyan Tariq Tagga

Muhammad Riyyan Tariq Tagga

Auto-generated profile, based on publicly available information

Muhammad Riyyan Tariq Tagga

CMH Multan Institute of Medical Sciences Multan Pakistan

Research Focus & Metrics

Academic Career Length

1Year (2026-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
30 April 2026 in Endocrinology, Diabetes & Metabolism
Verified
Journal Article
Open access
AQAhmar Jan Qureshi
Ahmar Jan Qureshi
MTMuhammad Riyyan Tariq Tagga
Muhammad Riyyan Tariq Tagga
RMRaghabendra Kumar Mahato
Raghabendra Kumar Mahato
Introduction: This critique examines the methodological quality of a recent study by Shahid et al. on mortality trends related to peripheral circulatory complications in patients with type 2 diabetes mellitus using the CDC WONDER database. Methods: We critically appraised the original study's methodology, including the consistency of reported mortality rates, age group data presentation, classification of urban and rural areas, reporting of race and ethnicity data, place of death analysis and causal inferences drawn from the ecological design. Results: Several methodological shortcomings were identified: inconsistent reporting of mortality rate denominators (per 100,000 vs. per 1,000,000 population); selective reporting of age group data in the main text; use of a non‐standard threshold (500,000 population) for classifying urban and rural areas; inconsistent use of the ‘Non‐Hispanic’ qualifier for race and ethnicity categories; percentages summing to over 100% in the place of death analysis; and unsupported causal claims in the discussion. Conclusions: While the original study addresses an important public health concern, the identified methodological issues limit the interpretability of its findings. Addressing these concerns through consistent denominators, complete age‐stratified reporting and standard classifications would strengthen future research in this area.

13 May 2026 in Cardiovascular Drugs and Therapy
Verified
Journal Article
Closed access
PDF file
AQAhmar Jan Qureshi
Ahmar Jan Qureshi
MTMuhammad Riyyan Tariq Tagga
Muhammad Riyyan Tariq Tagga
AKAbdul Qayum Khan
Abdul Qayum Khan

21 July 2026 in International Journal of Retina and Vitreous
Verified
Journal Article
Open access
PDF file
AQAhmar Jan Qureshi
Ahmar Jan Qureshi
Ali Shan HafeezAli Shan Hafeez
Ali Shan Hafeez
HSHamna Hassan Siddiqui
Hamna Hassan Siddiqui
AZAhsab Zaka
Ahsab Zaka
MTMuhammad Riyyan Tariq Tagga
Muhammad Riyyan Tariq Tagga
ASAtiqullah Sadaqat
Atiqullah Sadaqat
Background: Diabetic tractional retinal detachment (TRD) secondary to proliferative diabetic retinopathy is a vision-threatening complication that may require pars plana vitrectomy in selected cases, particularly when the macula is threatened or detached. Silicone oil tamponade is commonly used in complex cases, although tamponade choice varies according to surgical findings and surgeon preference. Objectives: To evaluate surgical outcomes associated with adjunctive dexamethasone implant during pars plana vitrectomy with silicone oil or heavy silicone oil tamponade for diabetic tractional retinal detachment. Methods: A comprehensive literature search of PubMed, Scopus, Web of Science, and ClinicalTrials.gov was performed from inception through 2025. Randomized and non-randomized comparative studies assessing PPV with silicone oil with or without adjunctive dexamethasone implant were considered. Definitions of postoperative PVR and retinal redetachment were accepted as reported by the original studies; no individual-level imaging or independent photographic regrading was available. The anatomical outcome was an exploratory composite of study-reported postoperative proliferative vitreoretinopathy (PVR) and/or retinal redetachment outcomes. Because definitions and follow-up time points differed across studies, this outcome was not treated as a uniformly graded PVR endpoint. Randomized and non-randomized comparative studies were identified; randomized trials were prioritized for the main analysis, while the non-randomized study was considered separately because of serious risk of bias. Secondary outcomes included best-corrected visual acuity (BCVA), central subfield thickness (CST), ocular hypertension, and postoperative complications. The protocol was prospectively registered in the International Prospective Register of Systematic Reviews (PROSPERO: CRD420261283105) prior to the commencement of the review. Results: Four studies involving 305 eyes were included. In the main randomized-trial analysis, two studies comprising 123 eyes contributed to the exploratory study-reported postoperative proliferative/redetachment composite. The pooled estimate was highly imprecise (RR 0.20, 95% CI 0.00 to 16.06; I² = 0%) and did not provide conclusive evidence of benefit. In an exploratory sensitivity analysis including the non-randomized study, the estimate favored dexamethasone implant, but this analysis was subject to serious risk of bias. BCVA and CST findings were limited by small sample sizes, heterogeneity, and inconsistent reporting. Intraocular-pressure outcomes were not pooled because definitions and assessment time points differed across studies. Conclusion: Current evidence is insufficient to support routine adjunctive dexamethasone implant use during vitrectomy with silicone oil for diabetic tractional retinal detachment. The available studies provide only a hypothesis-generating signal of fewer study-reported postoperative proliferative or redetachment events. Use should remain selective and individualized until adequately powered randomized trials with standardized anatomical outcomes are available. Clinical trials number: Not applicable.

1 November 2026 in Influenza and Other Respiratory Viruses
Verified
Journal Article
Open access
PDF file
AQAhmar Jan Qureshi
Ahmar Jan Qureshi
MTMuhammad Riyyan Tariq Tagga
Muhammad Riyyan Tariq Tagga
HAHussnain Ali
Hussnain Ali
ATAliza Tariq
Aliza Tariq
MYModibo Yattassaye
Modibo Yattassaye
Background: The COVID‐19 pandemic and associated nonpharmaceutical interventions caused unprecedented suppression of influenza circulation globally. Pakistan, with its high population density and evolving surveillance capacity, lacks long‐term data on post‐COVID‐19 influenza patterns, essential for guiding vaccine policy. Methods: We extracted weekly virological data for Pakistan from the WHO FluNet platform (January 1, 2015, to December 31, 2024). The study period was divided into pre‐COVID‐19 (2015–2019), COVID‐19 disruption (2020–2021), and post‐COVID‐19 (2022–2024) phases. Outcomes included type A versus B proportion, subtype distribution (A[H1N1]pdm09 vs. A[H3]), positivity, peak intensity, and season duration (weeks with positivity ≥ 10%). Statistical comparisons used chi‐square for subtype distribution and Kruskal–Wallis for peak intensity. Results: We analyzed 6522 positive specimens from 79,484 tested (10,781 pre‐COVID‐19; 14,687 during COVID‐19 disruption; 54,016 post‐COVID‐19). Influenza A declined from 94.2% to 71.7% then rose to 77.5%; influenza B increased from 5.7% to 28.3%, remaining at 22.5% ( p < 0.001). A(H3) dominated during the COVID‐19 disruption (98.8%); A(H1N1)pdm09 regained dominance post‐COVID‐19 (58.8%), though A(H3) remained higher than pre‐COVID‐19 (41.2% vs. 33.3%). Peak intensity differed ( p = 0.047): pre‐COVID‐19 33.3%–67.6%; COVID‐19 disruption 14.0%–17.6%; and post‐COVID‐19 19.8%–37.8%. Season duration was 1 week in 2020 and 3 non‐consecutive weeks in 2021, versus 10–16 weeks pre‐COVID‐19, recovering to 7–13 weeks post‐COVID‐19. Conclusion: The COVID‐19 pandemic induced a lasting shift in Pakistan's influenza epidemiology, with persistently elevated influenza B and reshaped A subtype balance. These findings are consistent with the global disappearance of B/Yamagata and support consideration of trivalent vaccine formulations, though antigenic and genetic data remain necessary to confirm vaccine match.